Daniel R. Matlis is Founder and President of Axendia, a leading analyst firm providing trusted advice to life science and healthcare executives on business, technology and regulatory matters. He has over 25 years of experience in the industry spanning the entire health science value chain. Dan is an active member in FDA’s case for quality initiative and has presented Axendia’s research findings to industry executives and the FDA. He is a frequent lecturer at industry events and has published numerous research reports and articles on key issues facing the life science and healthcare industries.
